Avadel Pharmaceuticals Plc (AVDL)
21.64
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
Avadel Pharmaceuticals Research and Development Expense (TTM) : 39.89M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2025 | 39.89M |
| June 30, 2025 | 16.69M |
| March 31, 2025 | 16.48M |
| December 31, 2024 | 15.20M |
| September 30, 2024 | 13.28M |
| June 30, 2024 | 12.33M |
| March 31, 2024 | 12.50M |
| December 31, 2023 | 13.26M |
| September 30, 2023 | 17.14M |
| June 30, 2023 | 17.22M |
| March 31, 2023 | 17.54M |
| December 31, 2022 | 20.70M |
| September 30, 2022 | 16.58M |
| June 30, 2022 | 18.02M |
| March 31, 2022 | 20.24M |
| December 31, 2021 | 17.10M |
| September 30, 2021 | 20.28M |
| June 30, 2021 | 21.47M |
| March 31, 2021 | 18.76M |
| December 31, 2020 | 20.44M |
| September 30, 2020 | 22.91M |
| June 30, 2020 | 24.88M |
| March 31, 2020 | 31.12M |
| December 31, 2019 | 32.92M |
| September 30, 2019 | 31.25M |
| Date | Value |
|---|---|
| June 30, 2019 | 35.11M |
| March 31, 2019 | 36.71M |
| December 31, 2018 | 39.33M |
| September 30, 2018 | 45.37M |
| June 30, 2018 | 42.06M |
| March 31, 2018 | 36.96M |
| December 31, 2017 | 34.22M |
| September 30, 2017 | 35.57M |
| June 30, 2017 | 35.62M |
| March 31, 2017 | 36.43M |
| December 31, 2016 | 34.61M |
| September 30, 2016 | 26.30M |
| June 30, 2016 | 25.37M |
| March 31, 2016 | 24.97M |
| December 31, 2015 | 25.61M |
| September 30, 2015 | 26.08M |
| June 30, 2015 | 25.89M |
| March 31, 2015 | 25.43M |
| December 31, 2014 | 23.35M |
| September 30, 2014 | 19.66M |
| June 30, 2014 | 19.32M |
| March 31, 2014 | 19.88M |
| December 31, 2013 | 24.46M |
| September 30, 2013 | 28.68M |
| June 30, 2013 | 28.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Jazz Pharmaceuticals Plc | 815.61M |
| Perrigo Co. Plc | 95.00M |
| GH Research Plc | 46.71M |
| Cosmo NV | 36.52M |
| Alkermes Plc | 384.84M |